Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | C5AR1 | P21730 | 4/20 | 0.30 |
| ▸ | SCN1A | P35498 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464445 | 0.85 | SCN1A (0.35) | NR1H2NR1H3IRAK4WDR5SCN1A | |
| SCHEMBL19925114 | 0.85 | SCN1A (0.35) | NR1H2NR1H3IRAK4WDR5SCN1A | |
| SCHEMBL23770719 | 0.78 | IRAK4 (0.33) | IRAK4 | |
| SCHEMBL29464485 | 0.71 | IRAK4 (0.39) | IRAK4SCN1ASCN5ASCN8A | |
| SCHEMBL29464496 | 0.71 | IRAK4 (0.39) | IRAK4SCN1ASCN5ASCN8A | |
| SCHEMBL19951379 | 0.71 | IRAK4 (0.39) | IRAK4SCN1ASCN5ASCN8A | |
| SCHEMBL23651319 | 0.71 | IRAK4 (0.39) | IRAK4SCN1ASCN5ASCN8A | |
| SCHEMBL19927708 | 0.71 | IRAK4 (0.39) | IRAK4SCN1ASCN5ASCN8A | |
| SCHEMBL19951378 | 0.71 | IRAK4 (0.39) | IRAK4SCN1ASCN5ASCN8A | |
| Hydrochloric Acid SCHEMBL19927738 | 0.71 | IRAK4 (0.38) | IRAK4SCN1ASCN5ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | NR1H2 2274/4885NR1H3 3036/4885IRAK4 250/4885 |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | NR1H2 2274/4885NR1H3 3036/4885IRAK4 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.